Drug Trial Radar · NCT07174115
A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Apr 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to assess the efficacy and safety of HTMC0658 tablets in treating subjects with chronic rhinosinusitis without nasal polyps (CRSsNP).
Conditions
- Chronic Sinusitis Without Nasal Polyps
Interventions
HTMC0658Drug
HTMC0658 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Lund-MacKay (LMK) score on sinus CT scan at Week 12Time frame: Baseline to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Luoyang First People's Hospital
Luoyang, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.